Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75% Market Closed
Market Cap: 3.6B USD

During the last 3 months Axonics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Oct 2, 2024 by Keese Kari Leigh , who sold 25.3k USD worth of AXNX shares.

Last Transactions:
Keese Kari Leigh
$-25.3k
Noblett Karen
$-764.6k
Cohen Raymond W
$-2.4m
Keese Kari Leigh
$-236.3k
Ford Alfred J Jr
$-1.1m
Woock John
$-1.1m
Noblett Karen
$-1.1m
Noblett Karen
$-446.2k
Noblett Karen
$-59.8k
Dearen Danny L.
$-436.5k
Ford Alfred J Jr
$-920.7k
Ford Alfred J Jr
$-93k
Dearen Danny L.
$-380.6k
Dearen Danny L.
$-621.1k
Dearen Danny L.
$-120.1k
Dearen Danny L.
$-394.7k
Sama Rinda
$-911.7k
Sama Rinda
$-44.8k
Ford Alfred J Jr
$-32.7k
Dearen Danny L.
$-28.6k
Cohen Raymond W
$-71.6k
Noblett Karen
$-8.2k
Woock John
$-35.1k
Sama Rinda
$-476.6k
Ford Alfred J Jr
$-259.1k
Dearen Danny L.
$-476.6k
Cohen Raymond W
$-848.5k
Noblett Karen
$-132.6k
Woock John
$-207.3k
Woock John
$-188.9k
Cohen Raymond W
$-1.2m
Ford Alfred J Jr
$-1m
View All Transactions

During the last 3 months Axonics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Oct 2, 2024 by Keese Kari Leigh , who sold 25.3k USD worth of AXNX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Axonics Inc
Insider Trading Chart

Axonics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Axonics Inc
Last Insider Transactions

Global
Insiders Monitor

Axonics Inc
Glance View

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
36.17 USD
Overvaluation 49%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top